Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuland LaboratoriesNSE:NEULANDLAB -1.69%93 Debt-to-EBITDA is 0.24 as of Mar. 2026, which is 83% below its 10-year median of 1.43. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 93/100 and a GF Value™ of ₹16,103.17 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Neuland Laboratories ranks better than 72.9% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Neuland Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:NEULANDLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.2 Med: 1.43 Max: 6.5
Current: 0.5
During the past 13 years, the highest Debt-to-EBITDA Ratio of Neuland Laboratories was 6.50. The lowest was 0.20. And the median was 1.43.
NSE:NEULANDLAB's Debt-to-EBITDA is ranked better than 72.9% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs NSE:NEULANDLAB: 0.50
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Neuland Laboratories Debt-to-EBITDA Related Terms
Neuland Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NEULANDLAB vs ZTS, UTHR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Neuland Laboratories (NSE:NEULANDLAB) has a Debt-to-EBITDA of 0.24 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Neuland Laboratories. This is 83% below median its historical median of 1.43. Over the past decade, Neuland Laboratories' Debt-to-EBITDA has ranged from 0.20 to 6.50. According to the industry distribution chart, Neuland Laboratories ranks #187 out of 690 companies in the Drug Manufacturers industry, placing it in the top 27.1%.
Is Neuland Laboratories' Debt-to-EBITDA too high?
Neuland Laboratories' current Debt-to-EBITDA of 0.24 is 83% below median its 10-year median of 1.43. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 6.50. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Neuland Laboratories' value of 0.24 is 85.6% below this industry median. Based on the distribution chart, Neuland Laboratories ranks #187 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #187 out of 690 companies for Debt-to-EBITDA. This puts Neuland Laboratories in the upper half of its industry. The industry median Debt-to-EBITDA is 1.67. Neuland Laboratories' value of 0.24 is 85.6% below this benchmark. Historically, Neuland Laboratories' own Debt-to-EBITDA has ranged from 0.20 to 6.50 over the past decade. While the company's 10-year median is 1.43 vs. the industry median of 1.67, Neuland Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Debt-to-EBITDA of 0.24 is 85.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Neuland Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Debt-to-EBITDA is 0.24, which is 83% below median its own 10-year median of 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,103.17, compared to a current price of ₹18,434.00 — trading 14.5% above its estimated fair value. The current Debt-to-EBITDA is 0.24, which is 83% below median its 10-year median of 1.43 and 85.6% below the Drug Manufacturers industry median of 1.67. Neuland Laboratories' overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Debt-to-EBITDA is 0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹18,434.00 is trading 14.5% above its estimated GF Value™ of ₹16,103.17.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
Debt-to-EBITDA: 0.24 (83% below median its 10-year median of 1.43)
GF Value™: ₹16,103.17 vs. price of ₹18,434.00 (14.5% above fair value)
Industry Position: 85.6% below the Drug Manufacturers median (#187 of 690)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
93GF Score
Get the complete analysis for NSE:NEULANDLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
